Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.48 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.48 |
| ▸ | SLC6A12 | P48065 | 5/20 | 0.46 |
| ▸ | SLC6A11 | P48066 | 5/20 | 0.46 |
| ▸ | SLC6A13 | Q9NSD5 | 5/20 | 0.46 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.46 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.46 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.36 |
| ▸ | PLG | P00747 | 1/20 | 0.34 |
| ▸ | PLAT | P00750 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2255221 | 1.00 | ANPEP (0.48) | ANPEPENPEPSLC6A12SLC6A11SLC6A13 | |
| SCHEMBL1861522 | 1.00 | ANPEP (0.48) | ANPEPENPEPSLC6A12SLC6A11SLC6A13 | |
| SCHEMBL607385 | 0.97 | ANPEP (0.47) | ANPEPENPEPSLC6A12SLC6A11SLC6A13 | |
| Potassium SCHEMBL607387 | 0.97 | ANPEP (0.47) | ANPEPENPEPSLC6A12SLC6A11SLC6A13 | |
| SCHEMBL24483431 | 0.89 | ANPEP (0.56) | ANPEPENPEPSLC6A12SLC6A11SLC6A13 | |
| SCHEMBL74792 | 0.89 | — | — | |
| SCHEMBL28300354 | 0.89 | ANPEP (0.56) | ANPEPENPEPSLC6A12SLC6A11SLC6A13 | |
| SCHEMBL1493230 | 0.89 | ANPEP (0.56) | ANPEPENPEPSLC6A12SLC6A11SLC6A13 | |
| SCHEMBL24197646 | 0.89 | ANPEP (0.56) | ANPEPENPEPSLC6A12SLC6A11SLC6A13 | |
| SCHEMBL431287 | 0.89 | ANPEP (0.56) | ANPEPENPEPSLC6A12SLC6A11SLC6A13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118961905-A | Craniopharyngeoma serum metabolite spectrum, intestinal flora spectrum and application thereof | 复旦大学附属华山医院 | 2024-11-15 | — | — | CN | claimed |
| CN-117214314-B | Organic acid content detection box and detection method | 深圳爱湾智造科技有限公司 | 2024-06-07 | — | — | CN | claimed |
| CN-117214314-A | Organic acid content detection box and detection method | 深圳爱湾智造科技有限公司 | 2023-12-12 | — | — | CN | claimed |
| CN-116298235-A | Serum metabolism biomarker for diagnosing or monitoring breast cancer and screening method thereof | 哈尔滨医科大学 | 2023-06-23 | — | — | CN | claimed |
| WO-2017189528-A1 | CORROSION INHIBITOR COMPOSITIONS AND METHODS OF USING SAME | Ecolab USA, Inc. (US) | 2017-11-02 | — | — | WO | claimed |
| US-20170306504-A1 | CORROSION INHIBITOR COMPOSITIONS AND METHODS OF USING SAME | CHAMPIONX LLC | 2017-10-26 | — | — | US | claimed |
| US-7993931-B1 | Oxygen-18 labeled organic acids and use in diagnosing metabolic disorders | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED (US) | 2011-08-09 | — | — | US | claimed |
| EP-4646197-A2 | ORGANIC COMPOUNDS AS NLRP3 INHIBITORS | Kodiak Sciences Inc. (US) | 2025-11-12 | — | — | EP | disclosed |
| US-20250288683-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2025-09-18 | — | — | US | disclosed |
| EP-4519272-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| EP-4519259-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| CN-118961905-A | Craniopharyngeoma serum metabolite spectrum, intestinal flora spectrum and application thereof | 复旦大学附属华山医院 | 2024-11-15 | — | — | CN | disclosed |
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2024-07-18 | — | — | US | disclosed |
| EP-1636223-A1 | BENZOTHIAZOLE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | F. Hoffman-la Roche AG (CH) | 2006-03-22 | — | — | EP | disclosed |
| WO-2005000842-A1 | BENZOTHIAZOLE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMAN-LA ROCHE AG (CH) | 2005-01-06 | — | — | WO | disclosed |
| US-20040235915-A1 | Benzothiazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-25 | — | — | US | disclosed |
| CN-1440410-A | Diazabicyclic central nervous system active agents | ABBOTT LAB (US) | 2003-09-03 | — | — | CN | disclosed |
| US-5753670-A | ANTICOAGULANTS | THE GREEN CROSS CORPORATION (JP) | 1998-05-19 | — | — | US | disclosed |
| US-5635527-A | ANTAGONIST OF PLATELET MEMBRANE GLYCOPROTEIN; TREATMENT OF THROMBOTIC DISEASES | THE GREEN CROSS CORPORATION (JP) | 1997-06-03 | — | — | US | disclosed |
| EP-0712844-A1 | NOVEL FUSED-RING CARBOXYLIC ACID COMPOUND OR SALT THEREOF, AND MEDICINAL USE THEREOF | THE GREEN CROSS CORPORATION (JP) | 1996-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235915-A1 | Benzothiazole derivatives | ADORA1, ADORA2A, ADORA3 | ANPEP 3271/4885ENPEP 4298/4885SLC6A12 502/4885 |
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2A1, BCL2L1, BCL3 | ANPEP 2335/4885ENPEP 1115/4885SLC6A12 4242/4885 |
| US-20250288683-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2L1, BCL2, BCL2L10 | ANPEP 3304/4885ENPEP 2524/4885SLC6A12 4744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.